[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[2] Xie P, Guo L, Yu Q, et al. ACE2 Enhances sensitivity to PD-L1 blockade by inhibiting macrophage-induced immunosuppression and angiogenesis [J]. Cancer Res, 2025, 85(2): 299-313.
[3] De Visser K E, Joyce J A. The evolving tumor microenviron-ment: from cancer initiation to metastatic outgrowth [J]. Cancer Cell, 2023, 41(3): 374-403.
[4] Cheng Y, Song S, Wu P, et al. Tumor associated macrophages and TAMs-based anti-tumor nanomedicines [J]. Adv Healthc Mater, 2021, 10(18): e2100590.
[5] Verona F, Di Bella S, Schirano R, et al. Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction [J]. Front Immunol, 2025, 16: 1529847.
[6] Christofides A, Strauss L, Yeo A, et al. The complex role of tumor-infiltrating macrophages [J]. Nat Immunol, 2022, 23(8): 1148-1156.
[7] Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy [J]. Cancer Commun (Lond), 2022, 42(11): 1112-1140.
[8] Zhang Y, Rao Y, Lu J, et al. The influence of biophysical niche on tumor-associated macrophages in liver cancer [J]. Hepatol Commun, 2024, 8(11):e0569.
[9] Chen Z, Yang S, Zhao Z, et al. Smart tumor cell-derived DNA nano-tree assembly for on-demand macrophages reprogramming [J]. Adv Sci (Weinh), 2024, 11(10): e2307188.
[10] Li M Y, Ye W, Luo K W. Immunotherapies targeting tumor-associated macrophages (TAMs) in cancer [J]. Pharmaceutics, 2024, 16(7):865.
[11] Zhou B, Yang Y, Li C. SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-kappaB pathway [J]. Onco Targets Ther, 2019, 12: 2519-2529.
[12] Zhou B, Li C, Yang Y, et al. RIG-I promotes cell death in hepatocellular carcinoma by inducing M1 polarization of perineal macrophages through the RIG-I/MAVS/NF-kappaB pathway [J]. Onco Targets Ther, 2020, 13: 8783-8794.
[13] Wang Q, Cheng F, Ma T T, et al. Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3 [J]. Mol Cell Biochem, 2016, 415(1-2): 157-168.
[14] Xiang X, Wang J, Lu D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy [J]. Signal Transduct Target Ther, 2021, 6(1): 75.
[15] Singer M, Zhang Z, Dayyani F, et al. Modulation of tumor-associated macrophages to overcome immune suppression in the hepatocellular carcinoma microenvironment [J]. Cancers (Basel), 2024, 17(1): 66.
[16] Bartneck M, Schrammen P L, Mockel D, et al. The CCR2(+) macrophage subset promotes pathogenic angiogenesis for tumor vascularization in fibrotic livers [J]. Cell Mol Gastroenterol Hepatol, 2019, 7(2): 371-390.
[17] Zang M, Li Y, He H, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection [J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(12): 3759-3770.
[18] Guan F, Wang R, Yi Z, et al. Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets [J]. Signal Transduct Target Ther, 2025, 10(1): 93.
[19] Li X, Li R, Miao X, et al. Integrated single cell analysis reveals an atlas of tumor associated macrophages in hepatocellular carcinoma [J]. Inflammation, 2024, 47(6): 2077-2093.
[20] Xu M, Wang Y, Xia R, et al. Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting [J]. Cell Prolif, 2021, 54(10): e13115.
[21] Weng J, Wang Z, Hu Z, et al. Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy [J]. Cancer Res, 2024, 84(11): 1817-1833.
[22] Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade [J]. Gut, 2019, 68(9): 1653-1666.
[23] Wang J, Zhang X, Ma X, et al. Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma [J]. J Exp Clin Cancer Res, 2023, 42(1): 303.
[24] Xiang X, Wang K, Zhang H, et al. Blocking CX3CR1+ tumor-associated macrophages enhances the efficacy of anti-PD1 therapy in hepatocellular carcinoma [J]. Cancer Immunol Res, 2024, 12(11): 1603-1620.
[25] Yang Q, Cui M, Wang J, et al. Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to sorafenib [J]. Cell Death Dis, 2025, 16(1): 153.
[26] Yu X, Qian J, Ding L, et al. Galectin-1-induced tumor associated macrophages repress antitumor immunity in hepatocellular carcinoma through recruitment of tregs [J]. Adv Sci (Weinh), 2025, 12(11): e2408788.
[27] Du K, Li Y, Liu J, et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC [J]. Mol Ther, 2021, 29(4): 1572-1584.
[28] Ma J, Ma R, Zeng X, et al. Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy [J]. J Exp Clin Cancer Res, 2023, 42(1): 192.
[29] Yu M, Yu H, Wang H, et al. Tumor associated macrophages activated in the tumor environment of hepatocellular carcinoma: characterization and treatment (Review) [J]. Int J Oncol, 2024, 65(4): 100.
[30] Xia Y, Rao L, Yao H, et al. Engineering macrophages for cancer immunotherapy and drug delivery [J]. Adv Mater, 2020, 32(40): e2002054.
[31] Niu M, Yi M, Li N, et al. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC [J]. Exp Hematol Oncol, 2021, 10(1): 18.
[32] Chang C C, Dinh T K, Lee Y A, et al. Nanoparticle delivery of MnO(2) and antiangiogenic therapy to overcome hypoxia-driven tumor escape and suppress hepatocellular carcinoma [J]. ACS Appl Mater Interfaces, 2020, 12(40): 44407-44419.
[33] Turco V, Pfleiderer K, Hunger J, et al. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles [J]. Nat Commun, 2023, 14(1): 771.
[34] Parayath N N, Gandham S K, Leslie F, et al. Improved anti-tumor efficacy of paclitaxel in combination with microRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer [J]. Cancer Lett, 2019, 461: 1-9.
[35] Becherini C, Lancia A, Detti B, et al. Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review [J]. Strahlenther Onkol, 2023, 199(12): 1173-1190.
[36] Khan S U, Khan M U, Azhar Ud Din M, et al. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy [J]. Front Immunol, 2023, 14: 1166487.
[37] Proietto M, Crippa M, Damiani C, et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications [J]. Front Oncol, 2023, 13: 1164535.
[38] Andrade De Oliveira K, Sengupta S, Yadav A K, et al. The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness [J]. Front Endocrinol (Lausanne), 2023, 14: 1083048.
[39] Khizar H, Ali K, Wang J. From silent partners to potential therapeutic targets: macrophages in colorectal cancer [J]. Cancer Immunol Immunother, 2025, 74(4): 121.
[40] Shang Q, Zhang P, Lei X, et al. Insights into CSF-1/CSF-1R signaling: the role of macrophage in radiotherapy [J]. Front Immunol, 2025, 16: 1530890.
[41] Wu C J, Tsai Y T, Lee I J, et al. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment [J]. Oncoimmunology, 2018, 7(9): e1477459.
[42] Dallavalasa S, Beeraka N M, Basavaraju C G, et al. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis - current Status [J]. Curr Med Chem, 2021, 28(39): 8203-8236.
[43] Cortese N, Donadon M, Rigamonti A, et al. Macrophages at the crossroads of anticancer strategies [J]. Front Biosci (Landmark Ed), 2019, 24(7): 1271-1283.
[44] Haber P K, Castet F, Torres-Martin M, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma [J]. Gastroenterology, 2023, 164(1): 72-88 e18.
[45] Xie C, Zhou X, Liang C, et al. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer [J]. J Exp Clin Cancer Res, 2021, 40(1): 266.
[46] Liu Y, Xue R, Duan X, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors [J]. Life Sci, 2023, 326: 121790. |
